Effect of Resveratrol Treatment on the Pharmacokinetics of Diclofenac in Healthy Human Volunteers

Phytotherapy Research

Volumn 30, Issue 3, 2016, Pages 397-401

  Bedada, Satish Kumar ^a   Yellu, Narsimha Reddy ^a   Neerati, Prasad ^a  

^a KAKATIYA UNIVERSITY   (India)

Author keywords

CYP2C9 enzyme; diclofenac; drug phytochemical interactions; pharmacokinetics; resveratrol

Indexed keywords

CYTOCHROME P450 2C9; DICLOFENAC; RESVERATROL; CYP2C9 PROTEIN, HUMAN; PLANT EXTRACT; STILBENE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; SINGLE DRUG DOSE; HALF LIFE TIME; HERB DRUG INTERACTION; MALE; ORAL DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2C9; DICLOFENAC; HALF-LIFE; HEALTHY VOLUNTEERS; HERB-DRUG INTERACTIONS; HUMANS; MALE; PLANT EXTRACTS; STILBENES; YOUNG ADULT;

EID: 84959361360     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5539     Document Type: Article

References (20)

1. Alsanad SM, Williamson EM, Howard RL,. 2014. Cancer patients at risk of herb/food supplement-drug interactions: a systematic review. Phytother Res 28: 1749-1755.
2. Bedada SK, Nearati P,. 2015. Effect of resveratrol on the pharmacokinetics of carbamazepine in healthy human volunteers. Phytother Res 29: 701-706.
3. Brisdelli F, D'Andrea G, Bozzi A,. 2009. Resveratrol: a natural polyphenol with multiple chemopreventive properties. Curr Drug Metab 10: 530-546.
4. Casper RF, Quesne M, Rogers IM, et al,. 1999. Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol Pharmacol 56: 784-790.
5. Chow HH, Garland LL, Hsu CH, et al,. 2010. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Canc Prev Res 3: 1168-1175.
6. Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, Beaudeux JL,. 2010. Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 54: 7-16.
7. Das S, Das DK,. 2007. Anti-inflammatory responses of resveratrol. Inflamm Allergy Drug Targets 6: 168-173.
8. Davies NM, Anderson KE,. 1997. Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin Pharmacokinet 33: 184-213.
9. Detampel P, Beck M, Krähenbühl S, Huwyler J,. 2012. Drug interaction potential of resveratrol. Drug Metab Rev 44: 253-265.
10. Hippisley-Cox J, Coupland C, Logan R,. 2005. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 331: 1310-1316.
11. Izzo AA,. 2012. Interactions between herbs and conventional drugs: overview of the clinical data. Med Princ Pract 21: 404-428.
12. Jiménez-Andrade JM, Ortiz MI, Pérez-Urizar J, et al,. 2003. Synergistic effects between codeine and diclofenac after local, spinal and systemic administration. Pharmacol Biochem Behav 76: 463-471.
13. Kalantari H, Das DK,. 2010. Physiological effects of resveratrol. Biofactors 36: 401-406.
14. Krösser S, Neugebauer R, Dolgos H, Fluck M, Rost KL, Kovar A,. 2006. Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial. Eur J Clin Pharmacol 62: 277-284.
15. Meng Q, Liu K,. 2014. Pharmacokinetic interactions between herbal medicines and prescribed drugs: focus on drug metabolic enzymes and transporters. Curr Drug Metab 15: 791-807.
16. Mohutsky MA, Anderson GD, Miller JW, Elmer GW,. 2006. Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo. Am J Ther 13: 24-31.
17. Rajnarayana K, Venkatesham A, Krishna DR,. 2007. Bioavailability of diclofenac sodium after treatment with diosmin in healthy volunteers. Drug Metabol Drug Interact 22: 165-174.
18. Romano B, Pagano E, Montanaro V, et al,. 2013. Novel insights into the pharmacology of flavonoids. Phytother Res 27: 1588-1596.
19. Udenigwe CC, Ramprasath VR, Aluko RE, Jones PJ,. 2008. Potential of resveratrol in anticancer and anti-inflammatory therapy. Nutr Rev 66: 445-454.
20. Ushijima K, Tsuruoka S, Tsuda H, et al,. 2009. Cranberry juice suppressed the diclofenac metabolism by human liver microsomes, but not in healthy human subjects. Br J Clin Pharmacol 68: 194-200.